Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
89.37
-1.28 (-1.41%)
At close: Mar 3, 2025, 4:00 PM
89.39
+0.02 (0.02%)
After-hours: Mar 3, 2025, 4:10 PM EST
Novo Nordisk Employees
Novo Nordisk had 77,349 employees as of December 31, 2024. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$521,201
Profits / Employee
$181,248
Market Cap
399.00B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
Dec 31, 2019 | 43,258 | 56 | 0.13% |
Dec 31, 2018 | 43,202 | 520 | 1.22% |
Dec 31, 2017 | 42,682 | 711 | 1.69% |
Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
Dec 31, 2015 | 40,638 | -319 | -0.78% |
Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
Dec 31, 2003 | 18,756 | 751 | 4.17% |
Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
Dec 31, 1999 | 11,994 | 345 | 2.96% |
Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
AbbVie | 55,000 |
NVO News
- 3 days ago - Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug - Hagens Berman - PRNewsWire
- 4 days ago - Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S - GlobeNewsWire
- 4 days ago - 6 Stocks to Buy as European Markets Soar - Benzinga
- 6 days ago - Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long. - Market Watch
- 6 days ago - Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug – Hagens Berman - GlobeNewsWire
- 8 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - Accesswire
- 10 days ago - Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says - CNBC
- 11 days ago - Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO - GlobeNewsWire